Construction and functional analysis of an anti-human cervical carcinoma/anti-human CD3 single-chain bispecific antibody

Wu,Hong; Yao, Li; Chou,Lin; Yang,Jin‑Hua; Zhang,Yun‑Xiu; Li,Xiao‑Li; Shan,Bo‑Er

doi:10.3892/mmr.2016.5292

Construction and functional analysis of an anti-human cervical carcinoma/anti-human CD3 single-chain bispecific antibody

Authors:
- Hong Wu
- Li Yao
- Lin Chou
- Jin‑Hua Yang
- Yun‑Xiu Zhang
- Xiao‑Li Li
- Bo‑Er Shan
View Affiliations

Affiliations: Department of Gynecology, Zhengzhou People's Hospital, Zhengzhou, Henan 450003, P.R. China, Department of Pathology, Zhengzhou People's Hospital, Zhengzhou, Henan 450003, P.R. China, Department of Gynecologic Oncology, Cancer Hospital, Fudan University, Shanghai 200438, P.R. China
Published online on: May 18, 2016 https://doi.org/10.3892/mmr.2016.5292
Pages: 804-810

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to construct a single-chain bispecific antibody (scBsAb) against cervical carcinoma and to investigate its biological activities. The scBsAb was constructed using a genetic cloning technique and antigen binding activities were detected by ELISA. The iodogen method was used to analyze the pharmacokinetics. The Rosette formation test was used to detect the binding ability between peripheral blood lymphocytes (PBLs) and Cs1213 cervical cancer cells. In addition, the MTT method was performed to detect the killing effect of PBLs. The molecular weight of the scBsAb was ~60 kDa. The antigen binding activities of scBsAbs were compared with the anti‑human cervical carcinoma antibody single‑chain Fv fragment (CSAs‑1 scFv) and anti‑cluster of differentiation (CD)3 scFv (P>0.05). In addition, a pharmacokinetics assay demonstrated that compared with the two corresponding scFvs, scBsAbs exhibited a significantly prolonged retention time in the body (P<0.01). In addition, the number of rosettes formed by PBLs and Cs1213 cells in the scBsAb group was markedly greater than that in the scFv groups or the RPMI‑1640 group (P<0.05 and P<0.01, respectively). The killing activity of PBLs against scBsAb‑mediated Cs1213 cells was significantly greater than that mediated by the other antibodies (P<0.05). When the concentration of scBsAb was 40 µg/ml, the killing rate was 64.5%. Thus, anti‑human cervical carcinoma/anti‑CD3 scBsAbs may possess two types of antigen binding activity, prolong the duration in vivo and improve the killing activity of PBLs against cancer cells.

View Figures

View References

1	Dillner J: Trends over time in the incidence of cervical neoplasia in comparison to trends over time in human papillomavirus infection. J Clin Virol. 19:7–23. 2000. View Article : Google Scholar : PubMed/NCBI
2	Chames P and Baty D: Bispecific antibodies for cancer therapy. Curr Opin Drug Discov Devel. 12:276–283. 2009.PubMed/NCBI
3	Urbanska K, Lynn RC, Stashwick C, Thakur A, Lum LG and Powell DJ Jr: Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells. J Transl Med. 12:3472014. View Article : Google Scholar : PubMed/NCBI
4	Dreier T, Baeuerle PA, Fichtner I, Grün M, Schlereth B, Lorenczewski G, Kufer P, Lutterbüse R, Riethmüller G, Gjorstrup P and Bargou RC: T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct. J Immunol. 170:4397–4402. 2003. View Article : Google Scholar : PubMed/NCBI
5	Makkouk A and Weiner GJ: Cancer immunotherapy and breaking immune tolerance: New approaches to an old challenge. Cancer Res. 75:5–10. 2015. View Article : Google Scholar
6	Cartellieri M, Arndt C, Feldmann A, von Bonin M, Ewen EM, Koristka S, Michalk I, Stamova S, Berndt N, Gocht A, et al: TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity. Oncoimmunology. 2:e267702013. View Article : Google Scholar
7	Tang P, Li L, Zhou Y, Shen CC, Kang YH, Yao YQ, Yi C, Gou LT and Yang JL: The preparation of VEGFR1/CD3 bispecific antibody and its specific cytotoxicity against VEGFR1-positive breast cancer cells. Biotechnol Appl Biochem. Dec 12–2013.Epub ahead of print. PubMed/NCBI
8	English DP, Bellone S, Schwab CL, Roque DM, Lopez S, Bortolomai I, Cocco E, Bonazzoli E, Chatterjee S, Ratner E, et al: Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo. Cancer. 121:403–412. 2015. View Article : Google Scholar
9	Cheng M, Ahmed M, Xu H and Cheung NK: Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy. Int J Cancer. 136:476–486. 2015. View Article : Google Scholar :
10	Löffler A, Kufer P, Lutterbüse R, Zettl F, Daniel PT, Schwenkenbecher JM, Riethmüller G, Dörken B and Bargou RC: A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood. 95:2098–2103. 2000.
11	Yang JZ, Zhang Z, Ma L, Yao XS, Zhou MQ, Wang XB and Wang XN: Biologic properties of an anti-human ovarian carcinoma/anti-human CD3 single chain bispecific antibody. Ai Zheng. 24:787–791. 2005.In Chinese. PubMed/NCBI
12	Wang D, Wu GJ, Wang H, Wu WZ, Yang SL and Tan JM: Comparison of biologic activity of two anti-PSA/anti-CD3 bispecific single-chain antibodies. Zhonghua Nan Ke Xue. 13:8–12. 2007.In Chinese. PubMed/NCBI
13	Zhou Y, Gou LT, Mu B, Liao WC, He J, Ma C, Yao YQ and Yang JL: A fully human CD19/CD3 bi-specific antibody triggers potent and specific cytotoxicity by unstimulated T lymphocytes against non-Hodgkin's lymphoma. Biotechnol Lett. 34:1183–1191. 2012. View Article : Google Scholar : PubMed/NCBI
14	Li X, Chen W, Yang YC and Si LS: Establishment and characterization of a new squamous cell carcinoma cell line CS1213 from the human uterine cervix. Zhonghua Fu Chan Ke Za Zhi. 38:614–617. 2003.In Chinese.
15	Kipriyanov SM, Moldenhauer G, Martin AC, Kupriyanova OA and Little M: Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity. Protein Eng. 10:445–453. 1997. View Article : Google Scholar : PubMed/NCBI
16	Gruber M, Schodin BA, Wilson ER and Kranz DM: Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli. J Immunol. 152:5368–5374. 1994.PubMed/NCBI
17	de Rock E and Taylor N: An easy method of layering blood over Ficoll-Paque gradients. J Immunol Methods. 17:373–374. 1977. View Article : Google Scholar : PubMed/NCBI
18	Rossi DL, Rossi EA, Cardillo TM, Goldenberg DM and Chang CH: A new class of bispecific antibodies to redirect T cells for cancer immunotherapy. MAbs. 6:381–391. 2014. View Article : Google Scholar : PubMed/NCBI
19	Hoffmann SC, Wabnitz GH, Samstag Y, Moldenhauer G and Ludwig T: Functional analysis of bispecific antibody (EpCAMxCD3)-mediated T-lymphocyte and cancer cell interaction by single-cell force spectroscopy. Int J Cancer. 128:2096–2104. 2011. View Article : Google Scholar
20	Sharkey RM, Karacay H, Vallabhajosula S, McBride WJ, Rossi EA, Chang CH, Goldsmith SJ and Goldenberg DM: Metastatic human colonic carcinoma: Molecular imaging with pretargeted SPECT and PET in a mouse model. Radiology. 246:497–507. 2008. View Article : Google Scholar : PubMed/NCBI
21	Gary R, Voelkl S, Palmisano R, Ullrich E, Bosch JJ and Mackensen A: Antigen-specific transfer of functional programmed death ligand 1 from human APCs onto CD8+ T cells via trogocytosis. J Immunol. 188:744–752. 2012. View Article : Google Scholar
22	Stanglmaier M, Faltin M, Ruf P, Bodenhausen A, Schröder P and Lindhofer H: Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 × anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels. Int J Cancer. 123:1181–1189. 2008. View Article : Google Scholar : PubMed/NCBI
23	Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM and Marks JD: Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer. 77:1405–1412. 1998. View Article : Google Scholar : PubMed/NCBI
24	Asano R, Shimomura I, Konno S, Ito A, Masakari Y, Orimo R, Taki S, Arai K, Ogata H, Okada M, et al: Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics. MAbs. 6:1243–1254. 2014. View Article : Google Scholar : PubMed/NCBI
25	Le Gall F, Reusch U, Little M and Kipriyanov SM: Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody. Protein Eng Des Sel. 17:357–366. 2004. View Article : Google Scholar : PubMed/NCBI
26	Kragh-Hansen U, Chuang VT and Otagiri M: Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol Pharm Bull. 25:695–704. 2002. View Article : Google Scholar : PubMed/NCBI
27	Muller D, Karle A, Meissburger B, Höfig I, Stork R and Kontermann RE: Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem. 282:12650–12660. 2007. View Article : Google Scholar : PubMed/NCBI